MedTrace Logo

Anifrolumab Malignancy and Serious Infections Study

NCT07000110 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3195

Last updated 2026-05-20

No results posted yet for this study

Summary

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Conditions

Interventions

DRUG

Anifrolumab

Anifrolumab prescribed per local practice

Sponsors & Collaborators

  • IQVIA Pty Ltd

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-26
Primary Completion
2031-11-30
Completion
2031-11-30

Countries

  • Denmark
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07000110 on ClinicalTrials.gov